Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

3,323

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

March 31, 2011

Study Completion Date

December 31, 2012

Conditions
Breast Cancer
Interventions
DRUG

clodronate

1600 mg PO daily

DRUG

placebo

2 pills PO daily

Trial Locations (17)

32224

Mayo Clinic, Jacksonville

38103

University of Tennessee Cancer Institute, Memphis

38104

Danville Radiation Therapy Center, Memphis

57709

Rapid City Regional Hospital, Rapid City

58201

Altru Cancer Center, Grand Forks

79106

Harrington Cancer Center, Amarillo

Veterans Affairs Medical Center - Amarillo, Amarillo

96813

MBCCOP - Hawaii, Honolulu

98109

University of Washington School of Medicine, Seattle

85259-5404

CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

51101-1733

Siouxland Hematology-Oncology, Sioux City

39531-2410

Veterans Affairs Medical Center - Biloxi, Biloxi

58501-5505

Medcenter One Health System, Bismarck

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

05401

Fletcher Allen Health Care - University Health Center Campus, Burlington

23298-0037

MBCCOP - Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

SWOG Cancer Research Network

NETWORK

collaborator

North Central Cancer Treatment Group

NETWORK

lead

NSABP Foundation Inc

NETWORK

NCT00009945 - Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer | Biotech Hunter | Biotech Hunter